Pfizer 2Q numbers tumble as COVID-19 vaccine, treatment sales dry up
Crumbling COVID-19 vaccine and treatment sales chopped Pfizer's second-quarter earnings, but both the drugmaker and Wall Street expect a rebound in the back half of 2023. |!| Oklah…
